The preparation of radiolabeled monoclonal antibodies for human use

Human Antibodies

Volumn 18, Issue 4, 2009, Pages 145-156

  Tran, Ly ^a   Beijnen, Jos H ^a,b   Huitema, Alwin D R ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Good Manufacturing Practice; Immunoreactivity; Radiance safety; Radiolabeled monoclonal antibodies for human use; Radiolabeling procedure

Indexed keywords

1,3,4,6 TETRACHLORO 3A,6A DIPHENYLGLYCOURIL; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 3 ( 4 HYDROXYPHENYL)PROPIONIC ACID; ASCORBIC ACID; BOLTON HUNTER REAGENT I 125; BUFFER; C MOV18; CD20 ANTIBODY; CHELATING AGENT; GLYCOLIC ACID DERIVATIVE; HALIDE; IMMUNOGLOBULIN ANTIBODY; IODINE; IODINE 131; IODOGEN; LANTHANIDE; METAL DERIVATIVE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DF3; MONOCLONAL ANTIBODY M 195; N HYDROXYSUCCINIMIDE; PENTETIC ACID; PROPIONIC ACID DERIVATIVE; RADIOHALOGEN; RADIOISOTOPE; RADIOLABELED MONOCLONAL ANTIBODY; RADIOLANTHANIDE; RADIOMETAL; RITUXIMAB; RITUXIMAB I 131; TOSYLCHLORAMIDE SODIUM; UNCLASSIFIED DRUG;

CHELATION; DRUG COATING; DRUG CONJUGATION; DRUG DOSE COMPARISON; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MEGADOSE; GOOD MANUFACTURING PRACTICE; HALOGENATION; HUMAN; IMMUNOREACTIVITY; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PURIFICATION; QUALITY CONTROL; RADIOCHEMISTRY; RADIOIMMUNOTHERAPY; REVIEW; STOICHIOMETRY;

ANTIBODIES, MONOCLONAL; DRUG STABILITY; HUMANS; QUALITY CONTROL; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS;

EID: 75149118213     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/HAB-2009-0211     Document Type: Review

References (76)

1. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga and L. Norton, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med 344 (2001), 783-792.
2. M.D. Pegram, A. Lipton, D.F. Hayes, B.L. Weber, J.M. Baselga, D. Tripathy, D. Baly, S.A. Baughman, T. Twaddell, J.A. Glaspy and D.J. Slamon, Phase II study of receptorenhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment, J Clin Oncol 16 (1998), 2659-2671.
3. N.L. Berinstein, A.J. Grillo-Lopez, C.A. White, I. Bence- Bruckler, D. Maloney, M. Czuczman, D. Green, J. Rosenberg, P. McLaughlin and D. Shen, Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma, Ann Oncol 9 (1998), 995-1001.
4. P. McLaughlin, A.J. Grillo-Lopez, B.K. Link, R. Levy, M.S. Czuczman, M.E.Williams, M.R. Heyman, I. Bence-Bruckler, C.A. White, F. Cabanillas, V. Jain, A.D. Ho, J. Lister, K.Wey, D. Shen and B.K. Dallaire, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program, J Clin Oncol 16 (1998), 2825-2833.
5. N.J. van, Jr., E. Kim, S. Casper, F.J. Primus, S. Bennett, F.H. DeLand and D.M. Goldenberg, Radioimmunodetection of primary and metastatic ovarian cancer using radiolabeled antibodies to carcinoembryonic antigen, Cancer Res 40 (1980), 502-506.
6. D.M. Goldenberg and R.M. Sharkey, Radioimmunotherapy of non-Hodgkin's lymphoma revisited, J Nucl Med 46 (2005), 383-384.
7. D.M. Goldenberg and R.M. Sharkey, Advances in cancer therapy with radiolabeled monoclonal antibodies, Q J Nucl Med Mol Imaging 50 (2006), 248-264.
8. R.M. Sharkey and D.M. Goldenberg, Perspectives on cancer therapy with radiolabeled monoclonal antibodies, J Nucl Med 46(1) (2005), 115S-127S.
9. S.M. Larson, Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy, J Nucl Med 26 (1985), 538-545.
10. S.J. Horning, A.Younes,V. Jain, S. Kroll, J. Lucas, D. Podoloff and M. Goris, Efficacy and safety of tositumomab and iodine- 131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab, J Clin Oncol 23 (2005), 712-719.
11. T.E.Witzig, Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma, Semin Oncol 30 (2003), 11-16.
12. EudraLex, Good manufacturing practices: medicinal products for human and veterinary use, Volume 4 (2009).
13. International Commission on Radiological Protection, 1990 Recommendations of the international commission on radiological protection. ICRP publication 60, Annals of the ICRP 21 (1991), 1-3.
14. W.R. Hendee and F.M. Edwards, ALARA and an integrated approach to radiation protection, Semin Nucl Med 16 (1986), 142-150.
15. M.S. Kaminski, K.R. Zasadny, I.R. Francis, A.W. Milik, C.W. Ross, S.D. Moon, S.M. Crawford, J.M. Burgess, N.A. Petry and G.M. Butchko, Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody, N Engl J Med 329 (1993), 459-465.
16. I. Verel, G.W. Visser, M.J. Vosjan, R. Finn, R. Boellaard and G.A. van Dongen, High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131Iradioimmunotherapy, Eur J Nucl Med Mol Imaging 31 (2004), 1645-1652.
17. M.N. Lub-de Hooge, J.G. Kosterink, P.J. Perik, H. Nijnuis, L. Tran, J. Bart, A.J. Suurmeijer, S. de Jong, P.L. Jager and E.G. de Vries, Preclinical characterisation of 111In-DTPAtrastuzumab, Br J Pharmacol 143 (2004), 99-106.
18. P. Blauenstein, J.T. Locher, K. Seybold, H. Koprivova, G.A. Janoki, H.R. Macke, P. Hasler, A. Ammann, I. Novak-Hofer and A. Smith, Experience with the iodine-123 and technetium- 99m labelled anti-granulocyte antibody MAb47: a comparison of labelling methods, Eur J Nucl Med 22 (1995), 690-698.
19. J.M. Vose, P.J. Bierman, C. Enke, J. Hankins, G. Bociek, J.C. Lynch and J.O. Armitage, Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stemcell transplantation for relapsed non-Hodgkin's lymphoma, J Clin Oncol 23 (2005), 461-467.
20. A.E. Bolton andW.M. Hunter, The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent, Biochem J 133 (1973), 529-539.
21. P.J. Fraker and J.C. Speck, Jr., Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6- tetrachloro-3a,6a- diphrenylglycoluril, Biochem Biophys Res Commun 80 (1978), 849-857.
22. F.C. Greenwood, W.M. Hunter and J.S. Glover, The preparation of I-131-labelled human growth hormone of high specific radioactivity, Biochem J 89 (1963), 114-123.
23. D.F. Hayes, M.A. Noska, D.W.Kufe and M.R. Zalutsky, Effect of radioiodination on the binding of monoclonal antibody DF3 to breast carcinoma cells, Int J Rad Appl Instrum B 15 (1988), 235-241.
24. D. Kufe, G. Inghirami, M. Abe, D. Hayes, H. Justi-Wheeler and J. Schlom, Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors, Hybridoma 3 (1984), 223-232.
25. L. Tran, J.W. Baars, H.J. Maessen, C.A. Hoefnagel, J.H. Beijnen and A.D. Huitema, A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy, Cancer Biother Radiopharm 24 (2009), 103-110.
26. K.S. Weadock, R.M. Sharkey, D.C. Varga and D.M. Goldenberg, Evaluation of a remote radioiodination system for radioimmunotherapy, J Nucl Med 31 (1990), 508-511.
27. A.M. Robles, H.S. Balter, P. Oliver, M.M. Welling and E.K. Pauwels, Improved radioiodination of biomolecules using exhaustive Chloramine-T oxidation, Nucl Med Biol 28 (2001), 999-1008.
28. G.W. Visser, R.P. Klok, J.W. Gebbinck, T. ter Linden, G.A. van Dongen and C.F. Molthoff, Optimal quality (131)Imonoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODOGEN, J Nucl Med 42 (2001), 509-519.
29. A.O. Schaffland, F. Buchegger, M. Kosinski, C. Antonescu, C. Paschoud, C. Grannavel, R. Pellikka and A.B. Delaloye, 131I-rituximab: relationship between immunoreactivity and specific activity, J Nucl Med 45 (2004), 1784-1790.
30. J.M. Ferens, K.A. Krohn, P.L. Beaumier, J.P. Brown, I. Hellstrom, K.E. Hellstrom, J.A. Carrasquillo and S.M. Larson, High-level iodination of monoclonal antibody fragments for radiotherapy, J Nucl Med 25 (1984), 367-370.
31. K.S. Weadock, L.L. Anderson and A.I. Kassis, A simple remote system for the high-level radioiodination of monoclonal antibodies, J Nucl Med Allied Sci 33 (1989), 37-41.
32. T.M. Behr, M. Gotthardt, W. Becker and M. Behe, Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy. A review of standardized, reliable and safe procedures for clinical grade levels kBq to GBq in the Gottingen/ Marburg experience, Nuklearmedizin 41 (2002), 71-79.
33. T.K. Nikula, M. Bocchia, M.J. Curcio, G. Sgouros, Y. Ma, R.D. Finn and D.A. Scheinberg, Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity, Mol Immunol 32 (1995), 865-872.
34. E.C. Dijkers, E.G. de Vries, J.G. Kosterink, A.H. Brouwers and M.N. Lub-de Hooge, Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy, Curr Pharm Des 14 (2008), 3348-3362.
35. W.B. Nagengast, E.G. de Vries, G.A. Hospers, N.H. Mulder, J.R. de Jong, H. Hollema, A.H. Brouwers, G.A. van Dongen, L.R. Perk and M.N. Lub-de Hooge, In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft, J Nucl Med 48 (2007), 1313-1319.
36. S. Liu, Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides, Adv Drug Deliv Rev 60 (2008), 1347-1370.
37. M.W. Brechbiel, Bifunctional chelates for metal nuclides, Q J Nucl Med Mol Imaging 52 (2008), 166-173.
38. M.W. Brechbiel and O.A. Gansow, Backbone-substituted DTPA ligands for 90Y radioimmunotherapy, Bioconjug Chem 2 (1991), 187-194.
39. D.J. Hnatowich, D. Snook, G. Rowlinson, S. Stewart and A.A. Epenetos, Preparation and use of DTPA-coupled antitumor antibodies radiolabeled with yttrium-90, Targeted Diagn Ther 1 (1988), 353-374.
40. M. Roselli, J. Schlom, O.A. Gansow, M.W. Brechbiel, S. Mirzadeh, C.G. Pippin, D.E. Milenic and D. Colcher, Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies, Int J Rad Appl Instrum B 18 (1991), 389-394.
41. R. Reilly, N. Lee, S. Houle, J. Law and A. Marks, In vitro stability of EDTA and DTPA immunoconjugates of monoclonal antibody 2G3 labeled with indium-111, Int J Rad Appl Instrum A 43 (1992), 961-967.
42. J.K. Sosabowski and S.J. Mather, Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes, Nat Protoc 1 (2006), 972-976.
43. S. Liu, C.E. Ellars and D.S. Edwards, Ascorbic acid: useful as a buffer agent and radiolytic stabilizer for metalloradiopharmaceuticals, Bioconjug Chem 14 (2003), 1052-1056.
44. M.R. Lewis, A. Raubitschek and J.E. Shively, A facile, watersoluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates, Bioconjug Chem 5 (1994), 565-576.
45. L. Camera, S. Kinuya, K. Garmestani, M.W. Brechbiel, C. Wu, L.H. Pai, T.J. McMurry, O.A. Gansow, I. Pastan and C.H. Paik, Comparative biodistribution of indium- and yttriumlabeled B3 monoclonal antibody conjugated to either 2-(p- SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)- 1,4,7,10- tetraazacyclododecane tetraacetic acid (2B-DOTA), Eur J Nucl Med 21 (1994), 640-646.
46. L.E. Williams, M.R. Lewis, G.G. Bebb, K.G. Clarke, T.L. Odom-Maryon, J.E. Shively and A.A. Raubitschek, Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems, Bioconjug Chem 9 (1998), 87-93.
47. M.R. Lewis, J.Y. Kao, A.L. Anderson, J.E. Shively and A. Raubitschek, An improved method for conjugating monoclonal antibodies with N- hydroxysulfosuccinimidyl DOTA, Bioconjug Chem 12 (2001), 320-324.
48. M.R. Lewis, A. Raubitschek and J.E. Shively, A facile, watersoluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates, Bioconjug Chem 5 (1994), 565-576.
49. D.L. Kukis, S.J. Denardo, G.L. DeNardo, R.T. O'Donnell and C.F. Meares, Optimized conditions for chelation of yttrium 90-DOTA immunoconjugates, J Nucl Med 39 (1998), 2105-2110.
50. A. Hawe, J.C. Kasper, W. Friess and W. Jiskoot, Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress, Eur J Pharm Sci 38 (2009), 79-87.
51. N. Harn, C. Allan, C. Oliver and C.R. Middaugh, Highly concentrated monoclonal antibody solutions: direct analysis of physical structure and thermal stability, J Pharm Sci 96 (2007), 532-546.
52. C.H. Paik, M.A. Ebbert, P.R. Murphy, C.R. Lassman, R.C. Reba, W.C. Eckelman, K.Y. Pak, J. Powe, Z. Steplewski and H. Koprowski, Factors influencing DTPA conjugation with antibodies by cyclic DTPA anhydride, J Nucl Med 24 (1983), 1158-1163.
53. D.J. Hnatowich, F. Virzi and P.W. Doherty, DTPA-coupled antibodies labeled with yttrium-90, J Nucl Med 26 (1985), 503-509.
54. C.H. Paik, J.J. Hong, M.A. Ebbert, S.C. Heald, R.C. Reba and W.C. Eckelman, Relative reactivity of DTPA, immunoreactive antibody-DTPA conjugates, and nonimmunoreactive antibody-DTPA conjugates toward indium-111, J Nucl Med 26 (1985), 482-487.
55. L. Riechmann, M. Clark, H. Waldmann and G. Winter, Reshaping human antibodies for therapy, Nature 332 (1988), 323-327.
56. M.S. Co, N.M. Avdalovic, P.C. Caron, M.V. Avdalovic, D.A. Scheinberg and C. Queen, Chimeric and humanized antibodies with specificity for the CD33 antigen, J Immunol 148 (1992), 1149-1154.
57. K. Zimmermann, J. Grunberg, M. Honer, S. Ametamey, P.A. Schubiger and I. Novak-Hofer, Targeting of renal carcinoma with 67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging, Nucl Med Biol 30 (2003), 417-427.
58. K. Knogler, J. Grunberg, I. Novak-Hofer, K. Zimmermann and P.A. Schubiger, Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties, Nucl Med Biol 33 (2006), 883-889.
59. R.M. Reilly, D.A. Scollard, J.Wang, H. Mondal, P. Chen, L.A. Henderson, B.M. Bowen and K.A. Vallis, A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications, J Nucl Med 45 (2004), 701-708.
60. C.Wu, O.A. GansowandM.W. Brechbiel, Evaluation of methods for large scale preparation of antibody ligand conjugates, Nucl Med Biol 26 (1999), 339-342.
61. A. Eon-Duval, R.H. MacDuff, C.A. Fisher, M.J. Harris and C. Brook, Removal of RNA impurities by tangential flow filtration in an RNase-free plasmid DNA purification process, Anal Biochem 316 (2003), 66-73.
62. D.W. Kahn, M.D. Butler, D.L. Cohen, M. Gordon, J.W. Kahn and M.E.Winkler, Purification of plasmid DNA by tangential flow filtration, Biotechnol Bioeng 69 (2000), 101-106.
63. T. Lindmo, E. Boven, F. Cuttitta, J. Fedorko and P.A. Bunn, Jr., Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess, J Immunol Methods 72 (1984), 77-89.
64. T.H. Stollman, M.G. Scheer,W.P. Leenders, K.C.Verrijp, A.C. Soede, W.J. Oyen, T.J. Ruers and O.C. Boerman, Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody, Int J Cancer 122 (2008), 2310-2314.
65. N. Ferrara, Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications, Semin Oncol 29 (2002), 10-14.
66. D.R. Collingridge, V.A. Carroll, M. Glaser, E.O. Aboagye, S. Osman, O.C. Hutchinson, H. Barthel, S.K. Luthra, F. Brady, R. Bicknell, P. Price and A.L. Harris, The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography, Cancer Res 62 (2002), 5912-5919.
67. S. Matzku, H. Kirchgessner, W.G. Dippold and J. Bruggen, Immunoreactivity of monoclonal anti-melanoma antibodies in relation to the amount of radioactive iodine substituted to the antibody molecule, Eur J Nucl Med 11 (1985), 260-264.
68. C.W. Damen, H. Rosing, J.H. Schellens and J.H. Beijnen, Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry, J Pharm Biomed Anal 46 (2008), 449-455.
69. N. Jovanovic, A. Bouchard, G.W. Hofland, G.J. Witkamp, D.J. Crommelin andW. Jiskoot, Stabilization of IgG by supercritical fluid drying: optimization of formulation and process parameters, Eur J Pharm Biopharm 68 (2008), 183-190.
70. J.R. Lakowicz and G. Weber, Quenching of protein fluorescence by oxygen. Detection of structural fluctuations in proteins on the nanosecond time scale, Biochemistry 12 (1973), 4171-4179.
71. M.C. Chakrabarti, N. Le, C.H. Paik, W.G. De Graff and J.A. Carrasquillo, Prevention of radiolysis of monoclonal antibody during labeling, J Nucl Med 37 (1996), 1384-1388.
72. G.L. DeNardo, S.J. Denardo, B.W. Wessels, D.L. Kukis, N. Miyao and A. Yuan, 131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis, Cancer Biother Radiopharm 15 (2000), 547-560.
73. Q.A. Salako, R.T. O'Donnell and S.J. Denardo, Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations, J Nucl Med 39 (1998), 667-670.
74. H. Mohsin, J. Fitzsimmons, T. Shelton, T.J. Hoffman, C.S. Cutler, M.R. Lewis, P.S. Athey, G. Gulyas, G.E. Kiefer, R.K. Frank, J. Simon, S.Z. Lever and S.S. Jurisson, Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3, Nucl Med Biol 34 (2007), 493-502.
75. H.R. Maxon, III and H.S. Smith, Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer, Endocrinol Metab Clin North Am 19 (1990), 685-718.
76. G.B. Saha, J. Whitten and R.T. Go, Conditions of radioiodination with iodogen as oxidizing agent, Int J Rad Appl Instrum B 16 (1989), 431-433.